Association between perioperative β-blocker use and clinical outcome of non-cardiac surgery in coronary revascularized patients without severe ventricular dysfunction or heart failure

Jungchan Park, Jeayoun Kim, Ji Hye Kwon, Soo Jung Park, Jeong Jin Min, Sangmin Maria Lee, Hyeon-Cheol Gwon, Young Tak Lee, Myungsoo Park, Seung Hwa Lee

1 Department of Anesthesiology and Pain Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 2 Division of Cardiology, Department of Medicine, Heart Vascular Stroke Institute, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 3 Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 4 Department of Internal Medicine, Hallym University Dongtan Sacred Heart Hospital, Hwaseong, Korea

☯ These authors contributed equally to this work.
* shuaa.lee@samsung.com

Abstract

Perioperative use of β-blocker has been encouraged in patients undergoing non-cardiac surgery despite weak evidence, especially in patients without left ventricular systolic dysfunction (LVSD) or heart failure (HF). This study evaluated the effects of perioperative β-blocker on clinical outcomes after non-cardiac surgery among coronary revascularized patients without LVSD or HF. Among a total of 503 patients with a history of coronary revascularization (either by percutaneous coronary intervention or coronary arterial bypass grafts) undergoing non-cardiac surgery, those without severe LVSD defined by ejection fraction over 30% or HF were evaluated. The primary outcome was a composite of death, myocardial infarction, repeat revascularization, and stroke during 1-year follow-up. Perioperative β-blocker was used in 271 (53.9%) patients. During 1-year follow-up, we found no significant difference in primary outcome between the two groups on multivariate analysis (hazard ratio [HR], 1.01; confidence interval [CI] 95%, 0.56–1.82; P = 0.963). The same result was shown in propensity-matched population (HR, 1.25; CI 95%, 0.65–2.38; P = 0.504). In coronary revascularized patients without severe LVSD or HF, perioperative β-blocker use may not be associated with postoperative clinical outcome of non-cardiac surgery. Larger registry data is needed to support this finding.
Introduction

Coronary heart disease (CHD) is a well-known risk factor of non-cardiac surgery, and nearly half of postoperative mortality is caused by cardiac complications [1,2]. β-blockers, traditionally prescribed for hypertension, are the primary choice of treatment after myocardial infarction (MI) or chronic angina [3,4]. In addition, β-blockers have shown improved clinical outcome in patients with chronic heart failure (HF) [5,6]. In this regard, they have not only been recommended as first line therapy for patients with CHD, but also been proposed to reduce cardiac complications by moderating hemodynamic response in the perioperative period [2,7–9]. However, evidence for these recommendations has been questioned and there remains debate on the cardio-protective effects of perioperative β-blocker in non-cardiac surgery [10]. Recent studies suggest that perioperative β-blocker use may not be associated with postoperative clinical outcome in CHD patients, especially when left ventricular function is preserved [11–13].

We therefore conducted this study to investigate whether perioperative use of β-blocker is associated with postoperative clinical outcome of non-cardiac surgery in coronary revascularized patients without severe left ventricular systolic dysfunction (LVSD) or HF.

Methods

Study population and data collection

This study was a single-center retrospective study. From February 2010 to December 2015, 537 patients undergoing non-cardiac surgery were initially enrolled in our registry. Inclusion criteria were: 1) patients who had a history of coronary revascularization either by coronary arterial bypass graft or percutaneous coronary intervention or both, 2) patients who underwent non-cardiac surgery under general anesthesia. Exclusion criteria were 1) patients with HF, and 2) patients with ejection fraction lower than 30%. In patients with multiple non-cardiac surgeries, only the first surgery after coronary revascularization was left for analysis. Preoperative variables, including medications and postoperative clinical outcome data within 1-year follow-up were collected by a trained study coordinator using a standardized case report form. All patients were anonymously analyzed, and the study protocol was approved by the Institutional Review Board of Samsung Medical Center (IRB No. 2017-01-026).

Definitions and outcomes

During an in-hospital stay, it is institutional policy to investigate all current medications, and convert them to in-hospital prescriptions. After admission, the department of anesthesia independently investigates and double checks current medications, and fills in a standardized preoperative evaluation sheet. Preoperative evaluation at our institution starts at the outpatient department. Routine preoperative tests include liver and renal biochemistries, complete blood count, coagulation profile, serologic assays for viruses and plain chest film. Further evaluations including electrocardiography, echocardiography, pulmonary function test, and imaging studies are performed in a multidisciplinary manner if necessary. Along with medications, any past medical history related to risk of surgery is also contained in the preoperative evaluation sheet.

Surgical risk stratification was in accordance with 2014 European Society of Cardiology/Anesthesiology (ESC/ESA) guidelines [2]. Diabetes mellitus was defined as having a history of treatment such as medication and lifestyle intervention or diagnosis of type 1 or type 2 diabetes mellitus. Hypertension was self-reported or prescription of anti-hypertensives or systolic blood pressure >140 mm Hg at rest. Stroke was defined as brain hemorrhage, transient...
ischemic attack, and cerebral infarction. Dyslipidemia was self-reported or defined as prescription of lipid lowering agents. HF included diastolic heart failure with preserved left ventricular function, and was defined as a history of HF or use of loop diuretics on or during hospital stay.

The primary outcome was major adverse cardiovascular and cerebral events (MACCE), defined as a composite of all-cause death, myocardial infarction, repeat revascularization, and stroke during 1-year follow-up. Repeat revascularization included target vessel and non-target vessel revascularization. The secondary outcomes included intraoperative and postoperative parameters. Intraoperative parameters were hypotension, bradycardia, and adrenergic drug requirement. Postoperative parameters were MACCE during 30 days follow-up, and each of MACCE and the composite of all-cause death, myocardial infarction, and repeat revascularization during 1-year and 30-days follow-up.

**Statistical analysis**

Continuous variables are presented as mean ± standard deviation (SD) and categorical variables are presented as percentages. Differences between each group were compared using t-test or Wilcoxon rank-sum test for continuous variables, and Chi-square or Fisher’s exact test for categorical variables. Survival curves using Kaplan-Meier estimates were constructed and log-rank test was compared.

We hypothesized that the incidence of MACCE during 1-year follow-up is higher in the β-blocker group compared to the no β-blocker group. Based on previous studies, we expected 10% in the β-blocker group to be reduced to 6% in the no β-blocker group [14]. With 59 months for accrual period and an additional 12 months of follow-up, the power of this study (232 patients in the no beta-blocker group, 271 patients in the beta-blocker group) is about 81% assuming the time to MACCE occurrence is exponentially distributed [15].

Adjusted hazard ratio (HR) with 95% confidence interval (CI) was reported, using Cox regression based on covariates with clinical relevance or P < 0.1. The following were covariates for adjustment: age, sex, hypertension, current smoking, chronic kidney disease, dyslipidemia, and ESC/ESA surgical risk. We performed rigorous adjustments using propensity scores to reduce selection bias and potential confounding factors. After propensity score-matching, an absolute standardized difference < 10% for the measured covariate suggested an appropriate balance between the groups. In the propensity score-matched population, we compared HR for outcomes using a stratified Cox regression model. We also performed a subgroup analysis to reveal hidden interaction with history of myocardial infarction, surgical risk, preserved left ventricular systolic function, revascularization strategy, multivessel disease, and chronic kidney disease. Statistical analyses were performed with SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and R 3.0.3 (Vienna, Austria; http://www.R-project.org/). All tests were 2-tailed, and P < 0.05 was considered statistically significant.

**Result**

A total of 537 patients were initially enrolled. Twenty-two patients with ejection fraction under 30% and 12 patients with heart failure were excluded. As a result, 503 patients remained for analysis. Types of surgery are summarized in S1 Table.

**Baseline characteristics**

Patients were divided into two groups: 271 (53.9%) in the β-blocker group and 232 (46.1%) in the no β-blocker group. Preoperative variables are summarized in Table 1. The incidence of hypertension, current smoking, and dyslipidemia was higher in the β-blocker group. After performing propensity score-matching, matched data set of 197 pairs was generated by 1:1
individual matching without replacement. There was no significant imbalance between the two groups in the propensity-matched population (Table 1).

Clinical outcomes

On multivariate analysis, the incidence of MACCE on 1-year follow-up was not different between the two groups (HR, 1.01; CI 95%, 0.56–1.82; P = 0.963). The clinical outcomes in entire population are listed in Table 2. The propensity-matched population showed the same results on 1-year follow-up (HR, 1.25; CI, 0.65–2.38; P = 0.34). The results of the analysis in the propensity-matched population are summarized in Table 3. Clinical outcome during 30-days follow-up also showed no significant difference both in the entire and propensity-matched populations. Intraoperative events such as hypotension, bradycardia, and adrenergic drug requirement also showed no significant difference. The incidence of intraoperative events is summarized in S2 Table. Kaplan-Meier Curves for the primary outcome in the entire and propensity-matched populations are shown in Fig 1.

The result of subgroup analysis is shown in the hazard-ratio plots in Fig 2. There were no significant interactions between perioperative β-blocker use and preoperative variables of interest such as myocardial infarction, surgical risk, preserved left ventricular systolic function, and other factors.

Table 1. Baseline characteristics.

|                       | Entire population        | P-value | Propensity-matched population |
|-----------------------|--------------------------|---------|-------------------------------|
|                       | β-blocker (N = 271)      |         |                               |
|                       | No β-blocker (N = 232)   |         |                               |
| Male                  | 201 (74.2)               | 0.262   | 101 (75.6)                  |
|                       | 182 (78.5)               |         | 154 (78.2)                  |
| Age                   | 68.9 (±8.8)              | 0.222   | -10.9                       |
|                       | 69.9 (±9.2)              |         | 69.4 (±8.5)                 |
|                       |                          |         | 69.7 (±9.0)                 |
| Diabetes              | 151 (55.7)               | 0.577   | -5.3                        |
|                       | 135 (58.2)               |         | 113 (57.4)                  |
|                       |                          |         | 116 (58.9)                  |
| Hypertension          | 226 (83.4)               | 0.02    | 22.3                        |
|                       | 174 (75)                 |         | 157 (79.7)                  |
|                       |                          |         | 160 (81.2)                  |
| Current smoking       | 25 (9.2)                 | 0.031   | 17                            |
|                       | 10 (4.3)                 |         | 12 (6.1)                    |
|                       |                          |         | 10 (5.1)                    |
| Chronic kidney disease| 71 (26.2)                | 0.071   | 15.6                        |
|                       | 45 (19.4)                |         | 42 (21.3)                  |
|                       |                          |         | 44 (22.3)                  |
| Dyslipidemia          | 224 (82.7)               | 0.035   | 20                             |
|                       | 174 (75)                 |         | 156 (79.2)                  |
|                       |                          |         | 151 (76.7)                  |
| Valvular heart disease| 20 (7.4)                 | 0.834   | 2                              |
|                       | 16 (6.9)                 |         | 15 (7.6)                    |
|                       |                          |         | 13 (6.6)                    |
| History of myocardial infarction | 68 (25.1)     | 0.482   | 6.4                          |
|                       | 52 (22.4)                |         | 41 (20.8)                    |
|                       |                          |         | 43 (21.8)                    |
| History of stroke     | 46 (17)                  | 0.757   | 1.9                          |
|                       | 37 (16)                  |         | 32 (16.2)                    |
|                       |                          |         | 33 (16.8)                    |
| History of PAD        | 72 (26.6)                | 0.154   | 11.7                         |
|                       | 49 (21.1)                |         | 47 (23.9)                    |
|                       |                          |         | 48 (24.4)                    |
| Multivessel disease   | 233 (86)                 | 0.262   | 10.3                         |
|                       | 191 (82.3)               |         | 164 (83.3)                  |
|                       |                          |         | 163 (82.7)                  |
| Ejection fraction < 50%| 213 (78.6)               | 0.355   | -8.2                        |
|                       | 190 (81.9)               |         | 162 (82.2)                  |
|                       |                          |         | 160 (81.2)                  |
| Hemoglobin            | 12.2 (±2.1)              | 0.926   | 0.8                          |
|                       | 12.2 (±2.1)              |         | 12.2 (±2.0)                 |
|                       |                          |         | 12.3 (±2.1)                 |
| Albumin               | 4.0 (±0.6)               | 0.339   | -93.9                        |
|                       | 4.5 (±8.8)               |         | 4.0 (±0.6)                  |
|                       |                          |         | 4.0 (±0.9)                  |
| Medication            | Aspirin                  | 0.183   | 13.3                         |
|                       | 178 (76.7)               |         | 154 (78.2)                  |
|                       |                          |         | 154 (78.2)                  |
|                       | Clopidogrel              | 0.342   | 8.1                          |
|                       | 110 (47.4)               |         | 98 (49.8)                    |
|                       |                          |         | 92 (46.7)                    |
|                       | ACEi/ARB                 | 0.813   | 1.7                          |
|                       | 102 (44)                 |         | 88 (44.7)                    |
|                       |                          |         | 85 (43.2)                    |
| ESC/ESA surgical risk | Mild                     | 0.055   |                               |
|                       | 35 (12.9)                |         | 29 (14.7)                    |
|                       | 48 (20.7)                |         | 30 (15.2)                    |
|                       | Intermediate            | 169 (62.4)| 127 (54.7)| 16.2               |
|                       | 127 (54.7)               |         | 120 (60.9)                  |
|                       | 118 (59.9)               |         | 2.1                          |
|                       | High                     | 67 (24.7)| 57 (24.6)| -0.3             |
|                       | 57 (24.6)                |         | 48 (24.4)                    |
|                       | 49 (24.9)                |         | -1.2                        |
|                       | Emergency                | 35 (12.9)| 38 (16.4)| 0.272            |
|                       | 38 (16.4)                |         | 28 (14.2)                    |
|                       | 29 (14.2)                |         | -1.5                        |
|                       | CABG                     | 148 (54.6)| 110 (47.4)| 0.107            |
|                       | 110 (47.4)               |         | 98 (49.8)                    |
|                       | 96 (48.7)                |         | 2                            |

Data are presented as mean ± standard deviation or n (%). PAD, peripheral arterial disease; ACEi, angiotensin converting enzyme inhibitor; ARB, aldosterone receptor blocker; ESC, European society of cardiology; ESA, European Society of Anaesthesiology; CABG, coronary arterial bypass grafting

https://doi.org/10.1371/journal.pone.0201311.t001
Table 2. Clinical outcomes in entire population.

|                | Univariate analysis | Multivariate analysis |
|----------------|---------------------|-----------------------|
|                | β-blocker (N = 271) | No β-blocker (N = 232) | Unadjusted HR (95% CI) | P-value | *Adjusted HR (95% CI) | P-value |
| 1-year follow-up |                     |                       |                         |         |                      |         |
| MACCE          | 24 (8.9)            | 23 (9.9)              | 0.87 (0.49–1.54)        | 0.63    | 1.01 (0.56–1.82)     | 0.963   |
| All-cause death| 12 (4.4)            | 11 (4.7)              | 0.90 (0.40–2.05)        | 0.81    | 1.26 (0.54–2.95)     | 0.594   |
| MI             | 9 (3.3)             | 5 (2.2)               | 1.53 (0.51–4.56)        | 0.44    | 1.64 (0.54–5.00)     | 0.385   |
| Stroke         | 2 (0.7)             | 2 (0.9)               | 0.33 (0.06–1.70)        | 0.185   | 0.33 (0.06–1.75)     | 0.193   |
| RR             | 9 (3.3)             | 7 (3.7)               | 1.08 (0.40–2.89)        | 0.886   | 1.06 (0.39–2.89)     | 0.909   |
| Death, MI or RR| 22 (8.1)            | 19 (8.2)              | 0.97 (0.53–1.80)        | 0.926   | 1.16 (0.62–2.18)     | 0.646   |
| 30-day follow-up|                    |                       |                         |         |                      |         |
| MACCE          | 11 (4.1)            | 11 (4.7)              | 0.85 (0.37–1.97)        | 0.71    | 0.95 (0.41–2.24)     | 0.91    |
| All-cause death| 1 (0.4)             | 7 (3.0)               | 0.12 (0.02–0.98)        | 0.048   | 0.17 (0.02–1.44)     | 0.105   |
| MI             | 7 (2.6)             | 2 (0.9)               | 3.01 (0.63–14.48)       | 0.17    | 3.07 (0.62–15.08)    | 0.168   |
| Stroke         | 2 (0.7)             | 5 (2.2)               | 0.84 (0.12–5.95)        | 0.86    | 0.81 (0.11–5.89)     | 0.838   |
| RR             | 8 (3.0)             | 3 (1.3)               | 2.28 (0.60–8.58)        | 0.224   | 2.21 (0.58–8.45)     | 0.246   |
| Death, MI or RR| 9 (3.3)             | 10 (4.3)              | 0.77 (0.31–1.89)        | 0.567   | 0.87 (0.35–2.19)     | 0.773   |

Data are presented as n (%). MACCE, major adverse cardiovascular and cerebral events; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; RR, repeat revascularization.

* Covariates include age, sex, hypertension, dyslipidemia, chronic kidney disease, current smoking and surgical risk

https://doi.org/10.1371/journal.pone.0201311.t002

Discussion

The present study shows that perioperative β-blocker use may not be associated with postoperative clinical outcomes of non-cardiac surgery in coronary revascularized patients without severe ventricular dysfunction, revascularization type, multivessel disease, and chronic kidney disease with respect to the primary outcome.

Table 3. Clinical outcomes in the propensity-matched population.

|                | β-blocker (N = 197) | No β-blocker (N = 197) | Adjusted HR (95% CI) | P-value |
|----------------|---------------------|-----------------------|----------------------|---------|
| 1-year follow-up |                     |                       |                      |         |
| MACCE          | 20 (10.2)           | 16 (8.1)              | 1.25 (0.65–2.38)     | 0.504   |
| All-cause death| 11 (5.6)            | 7 (3.6)               | 1.56 (0.62–3.88)     | 0.343   |
| MI             | 8 (4.1)             | 4 (2.0)               | 2.02 (0.60–6.78)     | 0.255   |
| Stroke         | 1 (0.5)             | 3 (1.5)               | 0.33 (0.03–3.18)     | 0.335   |
| RR             | 7 (3.6)             | 7 (3.6)               | 1.00 (0.35–2.89)     | 0.998   |
| Death, MI or RR| 19 (9.6)            | 14 (7.1)              | 1.36 (0.68–2.72)     | 0.386   |
| 30-day follow-up|                    |                       |                      |         |
| MACCE          | 9 (4.6)             | 8 (4.3)               | 1.13 (0.46–2.81)     | 0.793   |
| All-cause death| 1 (0.5)             | 5 (2.5)               | 0.20 (0.02–1.71)     | 0.14    |
| MI             | 6 (3.1)             | 2 (1.0)               | 3.03 (0.61–15.04)    | 0.176   |
| Stroke         | 1 (0.5)             | 1 (0.5)               | 0.99 (0.06–15.77)    | 0.994   |
| RR             | 7 (3.6)             | 3 (1.5)               | 2.34 (0.60–9.11)     | 0.22    |
| Death, MI or RR| 8 (4.1)             | 8 (4.1)               | 1.01 (0.40–2.55)     | 0.991   |

Data are presented as n (%). MACCE, major adverse cardiovascular and cerebral events; HR, hazard ratio; CI, confidence interval; MI, myocardial infarction; RR, repeat revascularization.

https://doi.org/10.1371/journal.pone.0201311.t003
Fig 1. Kaplan-Meier Curves for major adverse cardiovascular and cerebral events during 1-year follow-up in the entire (A) and propensity-matched (B) populations.

https://doi.org/10.1371/journal.pone.0201311.g001

Fig 2. Subgroup analysis of history of myocardial infarction, high-risk surgery, ejection fraction over 50%, coronary arterial bypass grafting as revascularization type, multivessel disease and chronic kidney disease for major adverse cardiovascular and cerebral events on 1-year follow-up.

https://doi.org/10.1371/journal.pone.0201311.g002
severe LVSD or HF. This finding suggests that routine use of β-blocker in every coronary revascularized patient during the perioperative period may not be reasonable.

β-blockers reduce key determinants of myocardial oxygen demand—heart rate, blood pressure, and stroke volume. Extrapolation of these benefits is especially valuable during the perioperative period, because surgical stress may cause type II MI. In this respect, current guidelines suggest continued treatment of β-blockers during the perioperative period in patients with previous β-blocker use. The 2002 ACC/AHA guideline was the first to strongly recommend perioperative β-blocker therapy in non-cardiac surgery, and they were mainly based on two randomized clinical trials [16,17]. After few modifications with conflicting evidence, the final recommendation of the 2009 ACC/AHA update was that it is reasonable to initiate β-blocker therapy before intermediate or high-risk surgery only in patients with established CHD [18–20]. The DECREASE (Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography) study has been the main evidence for mortality benefit [8]. However, with questions on the reliability of this study, the efficacy and safety of perioperative β-blocker therapy are still controversial [10]. Recent meta-analyses showed that perioperative β-blocker therapy may not be associated with improved clinical outcome [10,13]. The result of this study corresponds well with these recent results.

The use of β-blocker, as the cornerstone of pharmacotherapy in patients with CHD, is another issue. Other than reducing myocardial oxygen demand, β-blocker increases coronary blood flow with prolongation of diastole, and reduces the burden of angina in patients with obstructive coronary lesion [6,21]. International guidelines recommend use of β-blockers in all patients with acute MI regardless of LVSD or HF [22,23]. However, unlike patients with unstable symptoms in which β-blocker effects are well established, β-blocker effects in stable CHD has been questioned and these guidelines face an enormous challenge, especially in terms of long-term therapy in patients without LVSD or HF [24]. Indeed, most of the evidence of these guidelines predates the era of coronary revascularization. Coronary intervention may make a difference because it potentially preserves more viable and less arrhythmogenic myocardium compared to non-invasive treatment. Moreover, the beneficial effects of β-blocker given early after acute MI in hemodynamically stable patients, is largely driven by a reduction in ventricular arrhythmias and re-infarction, and the mortality advantage after 1 month of use in acute MI patients without LVSD is not known [25]. A meta-analysis on 10 observational studies among more than 40,000 patients showed that the beneficial effects of β-blocker after percutaneous coronary intervention is limited to those with reduced ejection fraction [26]. The most recent study also showed that among survivors after hospitalization due to acute MI without LVSD or HF, β-blocker therapy was not associated with lower all-cause mortality within 1-year follow-up [12].

β-blockers are not completely free from potential harms during the perioperative period. Many patients actually report side effects and many medications show decreased drug adherence [27]. In patients with lowest cardiac risk, perioperative β-blocker use was not associated with any benefit but even with harm [28]. It is also reported that perioperative β-blockers started within one day or less before non-cardiac surgery may be associated with increased risk of bradycardia, hypotension, stroke and even death [1]. We acknowledge that the circumstances of patients in this study are different, in that they pose a certain cardiac risk and showed no side effects of β-blocker from previous use. None of these intraoperative events were increased in this study. However, avoidance of hypotension is still critical in the postoperative period, and β-blocker is no longer recommended as a first line therapy of hypertension [29]. Therefore, in coronary revascularized patients, routine use of perioperative β-blockers may be preserved for patients who are tolerated by previous use, but not in every patient.
The strength of this study is that it is conducted in patients from coronary revascularization era. The results of our study showing neutral effect of perioperative β-blocker among coronary revascularized patients without severe LVSD, correspond with previous studies on patients with stable CHD and share a potential explanation for the inconsistent effect of β-blocker therapy [11,12]. β-blockers also showed neutral effects in patients undergoing coronary arterial bypass grafts [30]. This study has an adequate setting, which can easily translate the results into everyday clinical practice in the coronary revascularization era. Patients with stable symptoms after coronary revascularization, are commonly scheduled for non-cardiac surgery because prolonged life expectancy leads to higher chances of other pathological conditions requiring surgical treatment [31]. Results of this study showing a neutral effect of perioperative β-blocker in both short-term and long-term follow-up suggest that the addition of β-blocker for coronary revascularized patients during the perioperative period might not be necessary.

Although β-blocker use did not improve overall postoperative clinical outcome, perioperative β-blocker use, according to current guidelines, may have selectively affected those with a history of MI undergoing high-risk surgery. Therefore, we also performed a subgroup analysis to further evaluate interactions with cofactors including history of MI, preserved left ventricular systolic function, and high-risk surgery. In subgroup analysis, no significant interaction was found.

The result of this study must be appraised in the light of following limitations. First, as a nature of retrospective studies, confounding factors may have influenced the results. Even with a propensity score-matched analysis to adjust potential confounding factors, unmeasured factors could not be corrected. Duration of time interval between coronary revascularization and start of β-blocker use might have affected the results, because the benefit of β-blocker is known to be maximal in the early post-MI period. Total duration of β-blocker use could also have affected the results. However, accurate durations were not available in all patients and therefore were not analyzed. Second, the effects of β-blocker initiated immediately before surgery could not be evaluated because this study was only in patients who had been on β-blockers therapy. Third, patients on previous β-blocker might have higher risk, and this might not have been fully adjusted even after propensity matching. Despite these limitations, this is the first study to evaluate the effect of perioperative β-blockers in coronary revascularized patients.

Conclusion

In coronary revascularized patients without severe LVSD or HF, perioperative β-blocker use may not be associated with postoperative clinical outcome. Large registry data or randomized controlled trials are needed to support this finding.

Supporting information

S1 Table. Types of surgery.
(DOCX)

S2 Table. Intraoperative events.
(DOCX)

Author Contributions

Conceptualization: Seung Hwa Lee.

Data curation: Jungchan Park, Jeayoun Kim, Ji Hye Kwon, Soo Jung Park, Myungsoo Park, Seung Hwa Lee.
Formal analysis: Jungchan Park, Jeayoun Kim, Seung Hwa Lee.

Investigation: Myungsoo Park, Seung Hwa Lee.

Methodology: Jungchan Park, Jeayoun Kim, Soo Jung Park, Myungsoo Park, Seung Hwa Lee.

Supervision: Jeong Jin Min, Sangmin Maria Lee, Hyeon-Cheol Gwon, Young Tak Lee, Seung Hwa Lee.

Validation: Jeong Jin Min.

Visualization: Soo Jung Park.

Writing – original draft: Jungchan Park, Jeayoun Kim.

Writing – review & editing: Sangmin Maria Lee, Hyeon-Cheol Gwon, Young Tak Lee, Myungsoo Park, Seung Hwa Lee.

References

1. Fleisher LA, Fleischmann KE, Auerbach AD, Barnason SA, Beckman JA, Bozkurt B, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 130:e278–333. https://doi.org/10.1161/CIR.0000000000000106 PMID: 25085961

2. Kristensen SD, Knuuti J. New ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management. Eur Heart J. 2014; 35:2344–5. https://doi.org/10.1093/eurheartj/ehu285 PMID: 25104785

3. Abrams J. Clinical practice. Chronic stable angina. N Engl J Med. 2005; 352:2524–33. https://doi.org/10.1056/NEJMcp042317 PMID: 15958808

4. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiologic studies. BMJ. 2009; 338:b1665. https://doi.org/10.1136/bmj.b1665 PMID: 19454737

5. Foody JM, Farrell MH, Krumholz HM. beta-Blocker therapy in heart failure: scientific review. JAMA. 2002; 287:883–9. https://doi.org/10.1001/jama.287.7.883 PMID: 11851582

6. Belsey J, Savelieva I, Mugelli A, Camm AJ. Relative efficacy of antianginal drugs used as add-on therapy in patients with stable angina: A systematic review and meta-analysis. Eur J Prev Cardiol. 2015; 22:837–48. https://doi.org/10.1177/2047487314533217 PMID: 24776376

7. Task Force for the management of arterial hypertension of the European Society of Hypertension, Task Force for the management of arterial hypertension of the European Society of Cardiology. 2013 ESH/ESC Guidelines for the Management of Arterial Hypertension. Blood Press. 2013; 22:193–278. https://doi.org/10.3109/08037051.2013.812549 PMID: 23777479

8. Poldermans D, Schouten O, Bax J, Winkel TA. Reducing cardiac risk in non-cardiac surgery: evidence from the DECREASE studies. Eur Heart J Suppl. 2009; 11:A9–A14. https://doi.org/10.1093/eurheartj/ sup004

9. Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery; executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg. 2008; 106:685–712. https://doi.org/10.1213/ane.0000309024.28586.70 PMID: 18292406

10. Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of secure randomised controlled trials of beta-blockade to prevent perioperative death in non-cardiac surgery. Heart. 2014; 100:456–64. https://doi.org/10.1136/heartjnl-2013-304262 PMID: 23904357

11. Andersson C, Merie C, Jorgensen M, Gislason GH, Torp-Pedersen C, Overgaard C, et al. Association of beta-blocker therapy with risks of adverse cardiovascular events and deaths in patients with ischemic heart disease undergoing noncardiac surgery: a Danish nationwide cohort study. JAMA Intern Med. 2014; 174:336–44. https://doi.org/10.1001/jamainternmed.2013.11349 PMID: 24247428

12. Dondo TB, Hall M, West RM, Jemberg T, Lindahl B, Bueno H, et al. beta-Blockers and Mortality After Acute Myocardial Infarction in Patients Without Heart Failure or Ventricular Dysfunction. J Am Coll Cardiol. 2017; 69:2710–20. https://doi.org/10.1016/j.jacc.2017.03.576 PMID: 28571635
Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol. Br J Anaesth. 2017; 118:11–21. https://doi.org/10.1093/bja/aew380 PMID: 28039238

Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357:1385–90. PMID: 11356434

Chow SC, Shao J, Wang H. Sample Size Calculations in Clinical Research. New York: Marcel Dekker—Biostatistics; 2017.

Hajibandeh S, Hajibandeh S, Antoniou SA, Torella F, Antoniou GA. Effect of beta-blockers on perioperative outcomes in vascular and endovascular surgery: a systematic review and meta-analysis. Br J Anaesth. 2017; 118:11–21. https://doi.org/10.1093/bja/aew380 PMID: 28039238

Poldermans D, Boersma E, Bax JJ, Thomson IR, van de Ven LL, Blankensteijn JD, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. N Engl J Med. 1999; 341:1789–94. https://doi.org/10.1056/NEJM199912034124202 PMID: 10588963

Poise Study Group, Devereaux PJ, Yang H, Yusuf S, Guyatt G, Leslie K, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet. 2008; 371:1839–47. https://doi.org/10.1016/S0140-6736(08)60601-7 PMID: 18479744

20. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography, et al. 2009 ACCF/AHA focused update on perioperative beta blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery, J Am Coll Cardiol. 2009; 54:e13–e118. https://doi.org/10.1016/j.jacc.2009.07.010 PMID: 19926002

21. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a double-blind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 1992; 19:409–17. PMID: 1732370

22. Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32:2999–3054. https://doi.org/10.1093/eurheartj/ehr236 PMID: 21873419

23. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr., Ganiats TG, Holmes DR Jr., et al. 2014 AHA/ACC guideline for the management of patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 64:e139–228. https://doi.org/10.1016/j.jacc.2014.09.017 PMID: 25260718

24. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012; 308:1340–9. https://doi.org/10.1001/jama.2012.12559 PMID: 23032550

25. Chen ZM, Pan HC, Chen YP, Peto R, Collins R, Jiang LX, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet. 2005; 366:1622–32. https://doi.org/10.1016/S0140-6736(05)67661-1 PMID: 16271643

26. Huang BY, Zuo ZL, Liao YB, Heng Y, Wang PJ, et al. Meta-Analysis of Relation Between Oral beta-Blocker Therapy and Outcomes in Patients With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention. J Am Cardiol. 2015; 10588963

27. Melloni C, Alexander KP, Ou FS, LaPointe NM, Roe MT, Newby LK, et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol. 2015; 115:1529–38. https://doi.org/10.1016/j.amjcard.2015.02.057 PMID: 25962157

28. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. N Engl J Med. 2005; 353:349–61. https://doi.org/10.1056/NEJMoa041895 PMID: 16049209

29. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel
members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311:507–20. https://doi.org/10.1001/jama.2013.284427 PMID: 24352797

30. Booij HG, Damman K, Warnica JW, Rouleau JL, van Gilst WH, Westenbrink BD. beta-blocker Therapy is Not Associated with Reductions in Angina or Cardiovascular Events After Coronary Artery Bypass Graft Surgery: Insights from the IMAGINE Trial. Cardiovasc Drugs Ther. 2015; 29:277–85. https://doi.org/10.1007/s10557-015-6600-y PMID: 26071975

31. Hawn MT, Graham LA, Richman JR, Itani KM, Plomondon ME, Altom LK, et al. The incidence and timing of noncardiac surgery after cardiac stent implantation. J Am Coll Surg. 2012; 214:658–66; discussion 666–7. https://doi.org/10.1016/j.jamcollsurg.2011.12.011 PMID: 22341201